REFERENCES
- Borgström E, Wahren B, Gustafson H. Fluorescence methods for measuring the A, B and H isoantigens on cytological material from bladder carcinoma. Urol Res 1985; 13: 43–45.
- Borgström E, Wahren B. Clinical significance of ABH isoantigen deletion of urothelial cells in bladder carcinoma. Cancer 1986; 58: 2428–2434.
- Cohen M. Urinary bladder carcinogenesis: Initiationpromotion. Semin Oncol 1979; 6: 157–160.
- Decenzo JM, Howard P, Irish CE. Antigenic deletion and prognoses of patients with stage A transitional cell bladder carcinoma. J Urol 1975; 114: 874–878.
- D'Elia FL, Cooper HS, Mulholland SG. ABH isoantigens in stage 0 papillary transitional carcinoma of the bladder: Correlation with biological behavior. J Urol 1982; 127: 665–667.
- Emmot RC, Javadpour N, Bergman SM, Soares T. Correlation of the cell surface antigens with stage and grade in cancer of the bladder. J Urol 1979; 121: 37–39.
- Gustafson H, Tribukait B. Characterization of bladder carcinomas by flow DNA analysis. Eur Urol 1985; 11: 410–417.
- Hakomori S. Philip Levine Award Lecture: Blood group antigens and their modifications as human cancer antigens. Am J Clin Pathol 1984; 82: 635–648.
- Harmer MH, ed. TNM classification of malignant tumors. 3rd ed. Geneva: UICC, 1978: 113–117.
- Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins I-R. Superficial bladder cancer. Progression and recurrence. J Urol 1983; 130: 1083–1086.
- Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes. JAMA 1974; 227: 281–286.
- Lange PH, Limas C, Fraley EE. Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J Urol 1978; 119: 52–55.
- Lange PH, Limas C. Molecular markers in the diagnoses and prognoses of bladder cancer. Urology 23, Suppl 1984: 46–54.
- Limas C, Lange P, Fraley EE, Vassella RL. A, B, H antigens in transitional cell tumors of the urinary bladder. Cancer 1979; 44: 2099–2107.
- Mostofi FK, Sorbin LH, Torloni H. International histological classification of urinary bladder tumors. No. 10. Geneva: WHO, 1974.
- Newman JrAJ, Carlton CE, Johnson S. Cell surface A, B or O (H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J Urol 1980; 124: 27–29.
- Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1.
- Richie JP, Blute JrRD and Waisman J. Immunologic indicators of prognoses in bladder cancer: the importance of cell surface antigens. J Urol 1980; 123: 22–24.
- Sandberg AA. Chromosome markers and progression in bladder cancer. Cancer Res 1977; 37: 2950.
- Soloway MS. Rational for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 1980; 123: 461–466.
- Tribukait B, Gustafson H, Esposti PL. The significance of ploidy and proliferation in the clinical and biological evaluation of bladder tumors: A study of 100 untreated cases. Br J Urol 1982; 54: 130–135.
- Tribukait B. Flow cytometry in surgical pathology and cytology of the genito-urinary tract. In:Koss LG, ed. Advances in Clinical Cytology. Vol 2. New York: Science Press, 1984: 163–189.
- Weinstein RS, Coon J, Alroy J, Davidsohn I. Tissue-associated blood group antigens in human tumors. In:DeLellis RA, ed. Diagnostic immunohistochemistry. New York, N.Y: Masson Publishing USA, 1981: 239–261.
- Wijkström H, Granberg-Öhman I, Tribukait B. Chromosomal and DNA patterns in transitional cell bladder carcinoma. A comparative cytogenetic and flow-cytofluorometric DNA study. Cancer 1984; 53: 1718–1723.